PLGF Molekülinformation
Molecule Name
Placental Growth Factor
Molekülalias
PGF,PLGF,PlGF,PGFL,SHGC-10760
Drug Development Progress
Anzahl der klinischen Arzneimittel11
Anzahl der inverkehr gebrachten Arzneimittel13
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
PGFL，Placental Growth Factor-Like，SHGC-10760，D12S1900，PlGF-2，PIGF，Placenta growth factor，PlGF，PGF，Placental Growth Factor，Placental Growth Factor， Vascular Endothelial Growth Factor-Related Protein
Molekülhintergrund
Placental growth factor (PGF) is also known as vascular endothelial growth factor-related protein, PLGF and PlGF2, is a member of the VEGF (vascular endothelial growth factor) sub-family - a key molecule in angiogenesis and vasculogenesis, in particular during embryogenesis. The main source of PGF during pregnancy is the placental trophoblast. PGF is also expressed in many other tissues, including the villous trophoblast. PGF is actived in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. PlGF2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth.
PLGF Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Aflibercept biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Macular Degeneration | Details | |
| 4D-150 | 4D-150 | Phase 3 Clinical | 4d Molecular Therapeutics Inc | Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Wet Macular Degeneration | Details |
| Aflibercept biosimilar (Shilpa Biologicals) | SBDM-03 | Phase 3 Clinical | Shilpa Biologicals Pvt Ltd | Wet Macular Degeneration | Details |
| Aflibercept Biosimilar(Rophibio) | RBS-001 | Phase 3 Clinical | Rophibio Inc | Macular Degeneration; Wet Macular Degeneration | Details |
| Aflibercept biosimiliar (Jingze Biotechnology) | JZB05; JZB-05 | Phase 3 Clinical | Chengdu Zeyan Biotechnology Co Ltd, Shanghai Jingze Biotechnology Co Ltd | Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Retinal Vein Occlusion | Details |
| Aflibercept biosimilar (Sam Chun Dang Pharm) | SCD-411 | Phase 3 Clinical | Sam Chun Dang Pharm Co Ltd | Macular Degeneration; Wet Macular Degeneration | Details |
| Anti-placental growth factor monoclonal antibody | αPlGF; R-7334; TB-403; RG-7334; THR-317; RO-5323441 | Phase 2 Clinical | Bioinvent International Ab, Thrombogenics | Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Mellitus; Diabetic Retinopathy; Glioblastoma; Macular Degeneration; Macular Edema; Medulloblastoma; Ovarian Neoplasms; Retinal Telangiectasis; Solid tumours | Details |
| PB-101 | PB-101 | Phase 1 Clinical | Panolos Bioscience Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| EB-105 | EB-105 | Phase 1 Clinical | Eluminex Biosciences (Suzhou) Ltd | Diabetic macular oedema; Diabetic Retinopathy | Details |
| Aflibercept biosimilar(Generium) | GNR-098 | Phase 1 Clinical | Generium Pharmaceuticals | Macular Degeneration | Details |
| Aflibercept biosimilar (Zein Bioteccnology) | Phase 1 Clinical | Zein Bioteccnology Co Ltd | Diabetic macular oedema | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Aflibercept Biosimilar (Alteogen) | ALT-L9 | Approved | Alteogen Inc, Kissei Pharmaceutical Co Ltd | EU | Diabetic macular oedema; Choroidal Neovascularization; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Biolitec Pharma Ltd | 2025-09-15 | Choroidal Neovascularization; Diabetic macular oedema; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details | |
| Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Approved | Momenta, Mylan Nv | YESAFILI | EU | Myopia, Degenerative; Diabetic Retinopathy; Retinal Vein Occlusion; Diabetes Complications; Macular Edema | Viatris Ltd | 2023-09-15 | Diabetes Complications; Diabetic macular oedema; Diabetic Retinopathy; Macular Edema; Myopia, Degenerative; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Aflibercept biosimilar (Qilu Pharmaceutical) | QL-1207; QL1207H | Approved | Qilu Pharmaceutical Co Ltd | 卓初明 | Mainland China | Macular Degeneration; Diabetic macular oedema | Qilu Pharmaceutical Co Ltd | 2023-12-13 | Diabetic macular oedema; Macular Degeneration; Wet Macular Degeneration | Details |
| Aflibercept biosimilar (Amgen) | ABP-938 | Approved | Amgen Inc | PAVBLU | United States | Diabetic Retinopathy; Macular Edema; Wet Macular Degeneration; Diabetic macular oedema | Amgen Inc | 2024-08-23 | Choroidal Neovascularization; Diabetes Complications; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Vascular Diseases; Wet Macular Degeneration | Details |
| Aflibercept biosimilar (Zaklady) | SDC411; SDC-411 | Approved | Zaklady Farmaceutyczne Polpharma SA | Vgenfli | EU | Choroidal Neovascularization; Retinal Vein Occlusion; Wet Macular Degeneration; Macular Edema; Diabetic macular oedema; Diabetes Complications | Zaklady Farmaceutyczne Polpharma SA | 2025-08-14 | Choroidal Neovascularization; Diabetes Complications; Diabetic macular oedema; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Aflibercept | BAY-865321; BAT-86-5321 | Approved | Bayer AG, Regeneron Pharmaceuticals Inc | Eylea, 艾力雅 | United States | Macular Degeneration; Macular Edema | Regeneron Pharmaceuticals Inc | 2011-11-18 | Carcinoma, Non-Small-Cell Lung; Cataract; Central Serous Chorioretinopathy; Choroid Diseases; Choroidal Neovascularization; Colonic Neoplasms; Colorectal Neoplasms; Corneal Neovascularization; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic macular oedema; Diabetic Retinopathy; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Glaucoma, Neovascular; Lymphoma, Non-Hodgkin; Macular Degeneration; Macular Edema; Multiple Myeloma; Myopia, Degenerative; Neoplasm Metastasis; Neoplasms; Polypoidal choroidal vasculopathy; Prostatic Neoplasms; Rectal Neoplasms; Retinal Degeneration; Retinal Diseases; Retinal Vein Occlusion; Retinitis Pigmentosa; Retinopathy of Prematurity; Vitreous Hemorrhage; Wet Macular Degeneration | Details |
| Aflibercept Biosimilar (Alvotech Swiss) | AVT-29; AVT-06 | Approved | Alvotech Swiss Ag | Mynzepli | EU | Wet Macular Degeneration; Macular Edema; Choroidal Neovascularization; Diabetes Complications; Retinal Vein Occlusion | Stada Arzneimittel Ag, null | 2025-08-18 | Choroidal Neovascularization; Diabetes Complications; Diabetic macular oedema; Eye Diseases; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Vascular Diseases; Wet Macular Degeneration | Details |
| Aflibercept biosimilar (HEXAL/Sandoz) | SOK-583A1; SOK583A1; SOK-583 | Approved | Hexal, Sandoz | ENZEEVU, Afqlir | United States | Wet Macular Degeneration | Sandoz Inc | 2024-08-09 | Diabetes Complications; Macular Degeneration; Macular Edema; Retinal Diseases; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Aflibercept biosimilar (Celltrion) | CT-P42 | Approved | Celltrion Inc | Eydenzelt | South Korea | Wet Macular Degeneration; Diabetic macular oedema | Celltrion Inc | 2024-05-30 | Choroidal Neovascularization; Diabetes Complications; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Ziv-aflibercept | AVE-0005; BAY-865321 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Zaltrap | United States | Colorectal Neoplasms | Sanofi-Aventis U.S. Llc | 2012-08-03 | Adenocarcinoma, Follicular; Ascites; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Glioma; Gliosarcoma; Leiomyosarcoma; Leukemia; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myelomonocytic, Chronic; Lung Diseases; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Metastatic breast cancer; Multiple Endocrine Neoplasia Type 1; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Neoplasm Metastasis; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Retinal Vein Occlusion; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Thyroid | Details |
| Aflibercept biosimilar (Bioeq) | FYB-203 | Approved | Formycon AG | AHZANTIVE, Baiama | United States | Diabetic Retinopathy; Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Retinal Vein Occlusion; Macular Degeneration | Formycon AG | 2024-06-28 | Choroidal Neovascularization; Diabetes Complications; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Aflibercept biosimilar (Samsung Bioepis) | SB-15; AM003; SB15 | Approved | Samsung Bioepis Co Ltd | OPUVIZ, Opuviz, AFILIVU | United States | Diabetic macular oedema; Macular Edema; Wet Macular Degeneration; Diabetic Retinopathy | Samsung Bioepis Co Ltd | 2024-05-20 | Diabetes Complications; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Aflibercept Biosimilar (Boan Biopharma/Luye Pharma） | LY-09004; BA-9101; OT-702 | Approved | Shandong Boan Biotechnology Co Ltd | 博优景 | Mainland China | Wet Macular Degeneration; Diabetic macular oedema | Shandong Boan Biotechnology Co Ltd | 2025-11-25 | Diabetic macular oedema; Macular Degeneration; Wet Macular Degeneration | Details |